Industries > Pharma > Generic Drugs Market Forecast 2018-2028

Generic Drugs Market Forecast 2018-2028

Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico

PUBLISHED: 25 April 2018
PAGES: 254
PRODUCT CODE: PHA0305

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE

The generic drugs market is estimated at $257.3bn in 2017 and is expected to grow at a CAGR of 7.9% from 2017 to 2028. The generic drugs market is expected to grow at a CAGR of 7.2% in the second half of the forecast period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 254-page report you will receive 66 tables and 84 figures– all unavailable elsewhere.

The 254-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Generic Drugs Market forecasts from 2018-2028

• Generic Drugs Regional Market and National Market forecasts from 2018-2028, covering:
• North America: US & Canada
• Europe: Germany, UK, France, Italy, Spain, Rest of Europe
• Asia-Pacific: Japan, Australia, India, China, South Korea, Rest of Asia-Pacific
• Middle East & Africa: South Africa, Saudi Arabia, U.A.E, Rest of Middle East & Africa
• Latin America: Brazil, Argentina, Mexico, Rest of Latin America

Generic Drugs Market Forecast 2018-2028

• SWOT Analysis and Porter’s Five Forces Analysis of the generic drugs market.

• Assessment of selected leading companies that hold major market shares in the generic drugs market.
• Teva
• Novartis (Sandoz)
• Allergan
• Mylan
• Pfizer
• Abbott
• Sun Pharma
• Aspen
• Fresenius Kabi
• Sanofi
• Dr. Reddy’s Laboratories
• Apotex

Visiongain’s study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.

Buy our report today Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets – North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1. Report Overview

1.1 Global Generic Drugs: Market Overview

1.2 Global Generic Drugs Market Segmentation

1.3 Why You Should Read This Report

1.4 How This Report Delivers

1.5 Key Questions Answered by This Analytical Report

1.6 Who is this Report for?

1.7 Methodology

1.8 Frequently Asked Questions (FAQs)

1.9 Associated Visiongain Reports

1.10 About Visiongain


2. An Introduction to Generic Drugs

2.1 An Introduction to the Rise of Generic Drugs

2.2 What Are Generic Drugs?

2.2.1 Generic Active Ingredients

2.3 A Brief Overview of the Pharmaceutical Industry

2.3.1 Brief History of Generic Drugs

2.3.2 The Hatch-Waxman Act: The Rise of Generics

2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics

2.5 Types of Generics – Authorised, Branded and Unbranded

2.6 Complex Generics

2.7 Classification of Generic Drugs Markets

2.8 Is Generic Substitution Bad News for Big Pharma Business?

2.8.1 The 'Ever greening' of Pharmaceutical Products

2.9 Regulation of Generic Drugs

2.9.1 Regulation in the US

2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs

2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs

2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry

2.9.1.4 How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?

2.9.1.5 How the Timing of Market Entry Influences Product Success

2.9.2 Regulation in Europe

2.9.2.1 EU Marketing Approval Procedures

2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity

2.9.2.3 Supplementary Protection Certificates

2.9.2.4 Variation in Drug Development Regulations between European Countries

2.9.2.5 The Move towards the Harmonisation of Standards

2.9.2.6 The Impact of Europe’s Unitary Patent System on Generic Drugs

2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing

2.9.3 Regulation in Japan

2.9.4 Regulation in China

2.10 Compulsory Licensing

2.11 Market Definition and Scope of This Report

2.11.1 Market Sizing and Revenue Reporting


3. Generic Drugs Market 2017-2028

3.1 The Global Generic Drugs Market: Market Overview

3.1.1 Segmenting the Global Generic Drugs Market

3.2 The Rise of the Global Generic Drugs Market in 2018

3.3 The Global Generic Drugs Market: Sales Forecast 2017-2028

3.4 Generic Drugs: Regional Market Forecast: 2017-2028

3.4.1 Changes in Generic Drug Regional Market Shares 2017-2028

3.5 National Markets That Will Drive Generic Drugs Growth

3.6 Changes in Market Shares by National Market 2017-2028

3.7 Drivers and Restraints for the Global Generic Drugs Market 2017-2028


4. North America Generic Drugs Market, 2017-2028

4.1 Generic Drugs in the North America: Market Overview

4.1.1 The Hatch-Waxman Act and Its Ongoing Effects

4.1.2 Consolidation in the Drug Development and Supply Chain Driving North America Generics

4.2 North America Generic Drugs Market: Drivers and Restraints 2017-2028

4.3 North America Generic Drugs Market Forecast: 2017-2028

4.4 Leading Companies Operating within the North America Generic Drugs Market

4.4.1 Increasing Acceptance of Generics amongst Consumers

4.4.2 Affordable Care Act: Expanding Medicare Coverage

4.5 North America Generic Drugs Market – Strategic Analysis

4.5.1 Will Biosimilars Dictate the Future of the US Generics Market?

4.5.2 The Backlog of ANDA Applications

4.5.3 The Generic Drug User Fee Amendments (GDUFA)

4.5.4 Shortages of Generic Drugs Will Restrain the Market

4.5.5 The Anti-Competitive ‘Pay for Delay’ Effect

4.6 US Generic Drugs Market: A Range of Factors Contributing to Growth

4.7 Canada Generic Drugs Market: A Range of Factors Contributing to Growth

4.8 North America Generic Drugs Market: Market Share Analysis


5. Europe Generic Drugs Market, 2017-2028

5.1 Generic Drugs in the Europe: Market Overview

5.1.1 Why Growth in Some Markets is Being Hindered?

5.1.2 Predominant Pricing Systems and Generic Penetration in European Markets

5.1.2.1 Lower Patient Co-Payments Drive Demand for Generics

5.1.2.2 The Effects of Tendering for Generic Medicines

5.1.3 Will Europe Move towards Free-Pricing Systems?

5.1.4 Challenges in the European Regulatory Environment

5.1.5 Ending Anti-Competitive ‘Pay for Delay’ Tactics in Europe

5.1.6 FDA and EMA Joint Data Sharing and Inspections

5.2 Europe Generic Drugs Market Forecast: 2017-2028

5.3 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry

5.4 UK Generic Drugs Market: A Mature Market with Growth Potentials

5.4.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration

5.5 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth

5.6 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth

5.6.1 The Tightening of Italy’s Patent Legislations

5.6.2 The Italian Healthcare System – A Tale of Falling Budgets

5.7 Spain Generic Drugs Market: Room for Growth

5.7.1 Cost-Containment Measures Helping to Boost Generic Drug Use

5.8 Europe Generic Drugs Market: Market Share Analysis


6. Asia-Pacific Generic Drugs Market, 2017-2028

6.1 Generic Drugs in the Asia-Pacific Market: Market Overview

6.2 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth

6.2.1 Leading Companies in the Indian Generic Drugs Market

6.2.2 Indian Generic Drugs Market: Sales Forecast 2017-2028

6.2.3 The Reforms to India’s Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues

6.2.4 Expansion of the National Healthcare Coverage Increases the Need for Generics

6.2.5 Has Recent Manufacturing Quality Failures Dented India’s Generics Growth?

6.3 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape

6.3.1 The Major Drivers of Growth in the Chinese Generics Market

6.3.2 Chinese Generic Drugs Market: Sales Forecast 2017-2028

6.3.3 Compulsory Licensing of Generic Drugs

6.3.4 Expansion of Healthcare Coverage and Reimbursement

6.3.5 The Impacts of Price Controls and the Anhui Model

6.4 Japanese Generic Drugs Market: High Barriers to Entry

6.4.1 Public Perception of Generics in Japan

6.4.2 Japanese Generic Drugs Market: Leading Companies

6.4.3 Government Initiatives Driving Generic Penetration

6.4.4 Japanese Attitudes to Generic Drugs

6.4.5 Japanese Generic Drugs Market: Sales Forecast 2017-2028

6.5 Australia Generic Drugs Market: Increased Market Access Supports the Market Growth

6.5.1 Australia Generic Drugs Market: Sales Forecast 2017-2028

6.6 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth

6.6.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea

6.6.2 KORUS FTA: The Free Trade Agreement between South Korea and the US

6.6.3 The Free Trade Agreement between Korea and the European Union

6.6.4 South Korean Generic Drugs Market: Sales Forecast 2017-2028

6.7 Asia-Pacific Generic Drugs Market: Market Share Analysis


7. Middle-East & Africa Generic Drugs Market, 2017-2028

7.1 Generic Drugs in the Middle-East & Africa Market: Market Overview

7.2 South Africa Generic Drugs Market:

7.2.1 South Africa Generic Drugs Market: Sales Forecast 2017-2028

7.3 Saudi Arabia Generic Drugs Market:

7.3.1 Saudi Arabia Generic Drugs Market: Sales Forecast 2017-2028

7.4 UAE Generic Drugs Market:

7.4.1 UAE Generic Drugs Market: Sales Forecast 2017-2028

7.5 Middle-East & Africa Generic Drugs Market: Market Share Analysis


8. Latin America Generic Drugs Market, 2017-2028

8.1 Generic Drugs in the Latin American Market: Market Overview

8.2 Brazil Generic Drugs Market:

8.2.1 Brazil Generic Drugs Market: Sales Forecast 2017-2028

8.3 Argentina Generic Drugs Market:

8.3.1 Argentina Generic Drugs Market: Sales Forecast 2017-2028

8.4 Mexico Generic Drugs Market:

8.4.1 Mexico Generic Drugs Market: Sales Forecast 2017-2028

8.5 Latin America Generic Drugs Market: Market Share Analysis


9. Leading Companies in the Generic Drugs Market, 2017-2028

9.1 Generic Drugs: Continuous Expansion to Rival

9.1.1 The Leading Companies in the Global Generics Market

9.2 Teva Pharmaceuticals Industries Limited

9.2.1 Teva: Historical Financial and Performance Analysis, 2013-2017

9.2.2 Teva Generic Drugs Sales Forecast 2017-2028

9.2.3 Teva acquired Allergan’s Generic Business Segment – Actavis Generic

9.2.3.1 Further Entry into the Japanese Generics Market

9.2.4 Teva: Generic Drugs Portfolio Analysis

9.2.4.1 High-Value Generics to Drive Teva’s Generics Growth?

9.2.4.2 The Shift towards Innovation

9.2.4.3 Copaxone Leads Teva’s Moving Focus

9.2.4.4 The Threat of Generic Erosion to Teva’s Products

9.2.4.5 Teva: What Future Moves Could We Expect?

9.3 Novartis

9.3.1 Novartis/Sandoz: Historical Financial and Performance Analysis, 2013-2017

9.3.2 Novartis/Sandoz Generic Drugs Sales Forecast 2017-2028

9.3.3 Novartis/Sandoz Generic Drugs Portfolio Analysis, 2017

9.3.3.1 Emphasis on Difficult-to-Manufacture Products

9.3.3.2 What Does the Future Hold for Novartis’ Generic Drugs Business?

9.4 Mylan

9.4.1 Mylan: Historical Financial and Performance Analysis, 2012-2016

9.4.2 Mylan Generic Drugs Sales Forecast 2017-2028

9.4.3 Mylan: Recent Developments

9.4.3.1 Acquisition of Meda AB

9.4.3.2 Acquisition of Abbott’s Generic Business

9.4.3.3 Mylan’s Growth in Manufacturing Capacity

9.4.3.4 Mylan Acquires Rights to GSK’s Advair, Diskus and Seretide

9.4.3.5 The Race to Market Copaxone Generics

9.4.3.6 Strategic Acquisition of Agila Expands Mylan’s Injectables Business

9.4.4 Mylan’s Collaborative Efforts

9.4.4.1 Biosimilar Collaboration with India’s Biocon

9.4.4.2 Biosimilar Collaborations with Momenta

9.4.4.3 What Does the Future Hold for Mylan’s Generic Drugs Business?

9.5 Pfizer

9.5.1 Pfizer: Historical Financial and Performance Analysis, 2012-2016

9.5.2 Pfizer’s Restructuring Strategy

9.5.3 Pfizer’s Done Deal with Hospira

9.5.4 Pfizer Generic Drugs Sales Forecast 2017-2028

9.5.5 Hospira: A Brief Overview of Operations

9.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015

9.5.7 Hospira: Recent Developments

9.5.7.1 Hospira’s Expansion through Strategic Acquisitions

9.5.7.2 Hospira: Manufacturing Concerns and Remediation Efforts

9.5.8 Future Prospects for Pfizer’s Generic Business

9.5.8.1 The Pfizer-Allergan Deal Falls Through

9.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger

9.5.8.3 Actavis’ Work on Biosimilars

9.6 Abbott

9.6.1 Abbott: Historical Financial and Performance Analysis, 2014-2016

9.6.2 Abbott Generic Drugs Sales Forecast 2017-2028

9.6.3 Abbott: Recent Developments

9.6.3.1 Abbott acquired St. Jude Medical

9.6.3.2 Abbott after the Spin-Off of AbbVie - The Established Products Business Segment

9.6.3.3 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions

9.6.3.4 Acquisition of CFR Pharmaceuticals Opens New Markets

9.6.4 What Does the Future Hold for Abbott’s Generic Drugs Business?

9.7 Sun Pharma

9.7.1 Sun Pharma’s Business Areas

9.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2011-2015

9.7.3 Sun Pharma Generic Drugs Sales Forecast 2017-2028

9.7.4 Sun Pharma-Ranbaxy Acquisition

9.8 Aspen

9.8.1 Aspen: Historical Financial and Performance Analysis, 2012-2017

9.8.2 Aspen Generic Sales Forecast 2017-2028

9.8.3 Aspen: Recent Developments

9.8.3.1 Aspen Acquires Merck MSD’s Dutch API Plant

9.8.3.2 Acquisition of GSK’s Anti-Thrombosis Brands

9.8.3.3 Future Outlook for Aspen’s Generic Business

9.9 Fresenius Kabi

9.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015

9.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2017-2028

9.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions

9.9.4 Fresenius Kabi’s Joint Venture with PT Soho Global Health

9.9.5 Future Prospects for Fresenius Kabi’s Generics Business

9.10 Sanofi

9.10.1 Sanofi: Historical Financial and Performance Analysis, 2011-2015

9.10.2 Sanofi Generic Sales Forecast 2017-2028

9.10.3 Sanofi’s Response to Lantus Competition

9.10.4 Emerging Market Acquisitions

9.10.5 Future Prospects for Sanofi’s Generics Business

9.11 Dr. Reddy’s Laboratories Limited

9.11.1 Dr. Reddy’s: Historical Financial and Performance Analysis, 2015-2017

9.11.2 Dr. Reddy’s Generic Sales Forecast 2017-2028

9.11.3 Dr. Reddy’s launched generic Azacitidine for Injection in the Canadian Market

9.11.4 The company acquired Imperial Credit Private Limited, a Non-Banking Finance Company

9.11.5 Dr. Reddy’s expanded its operations in the European region

9.12 Apotex, Inc.

9.12.1 Apotex expanded its manufacturing facilities in the U.S.

9.12.2 Apotex launched first Generic Version of Merck's Nasonex


10. Qualitative Analysis of the Generic Drugs Market, 2017-2028

10.1 Market Factors Influencing the Global Generic Drugs Market

10.2 SWOT Analysis of the Global Generic Drugs Market, 2017-2028

10.2.1 Strengths

10.2.1.1 Improving Clarity around Regulatory Processes

10.2.1.2 The Continuous Government Support for Generic Manufacturers – Precursors for Innovation

10.2.1.3 Higher Pace of Growth Compared with Innovative Pharma

10.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities

10.2.2 Weaknesses

10.2.2.1 Safety and Quality Concerns in the Manufacturing Process

10.2.2.2 The Non-Uniformity of Excipients

10.2.2.3 The Uncertainty around Patent Extensions and Exclusivities

10.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics

10.2.2.5 Inefficiencies in Certain Regulatory Approval Processes

10.2.3 Opportunities

10.2.3.1 Higher Value Biosimilars and Branded Generics

10.2.3.2 Patent Expiries Creating Opportunities

10.2.3.3 Changing Socio-Economic Conditions Impacting Generic Drugs Demand

10.2.3.4 Emerging Markets – Expected to Drive Generics Volume Growth over Time

10.2.4 Threats

10.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices

10.2.4.2 The Complexity Surrounding Patents and Patent Expiries

10.2.4.3 Pharmacies and Healthcare Payer Consolidations

10.2.4.4 Possible Impacts of a Declining Patent Pool

10.3 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017-2028

10.3.1 Power of Buyers: Medium

10.3.2 Power of Suppliers: Low

10.3.3 Rivalry among Competitors: High

10.3.4 Threat of New Entrants: High

10.3.5 Threat of Substitutes: Low


11. Conclusions

11.1 Overview of Current Market Conditions and Market Forecast, 2017-2028

11.1 Generic Drugs as a Strategic Tool in Healthcare

11.2 Major Drivers of Growth for Generic Drugs, 2017-2028

11.3 The Regulatory Landscape for Generic Drugs

11.4 Leading Generic Drug Manufacturers

11.5 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2028

11.6 What Does the Future Hold for the Global Generic Drugs Market?


Appendices

Glossary

Some Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form


List of Tables

Table 2.1 Types of Drug Names, 2017

Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Regional and National Markets, 2017 and 2018

Table 3.2 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2017-2028

Table 3.4 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2017, 2022, and 2028

Table 3.5 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022, 2022-2028, 2017-2028

Table 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2017, 2022, and 2028

Table 4.1 North America Generic Drugs Market: by Country Value ($bn), AGR (%), and CAGR (%), 2017 - 2028

Table 4.2 U.S. Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 4.3 Canada Generic Drugs Market Value ($bn), AGR (%), CAGR (%), 2017 - 2028

Table 5.1 Europe Generic Drugs Market: by Country Value ($bn), AGR (%) and CAGR (%) 2017 - 2028

Table 5.2 Germany Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 5.3 UK Generic Drugs Market Value ($bn), AGR (%) and CAGR (%) 2017 - 2028

Table 5.4 France Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 5.5 Italy Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028

Table 5.6 Spain Generic Drugs Market Value ($bn), AGR (%), and CAGR (%), 2017 - 2028

Table 6.1 India Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.2 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2017, 2022 & 2028

Table 6.3 China Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.4 Japan Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.5 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 6.6 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 7.1 South Africa Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 7.2 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 7.3 UAE Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 8.1 Brazil Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 8.2 Argentina Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 8.3 Mexico Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2016 and 2017

Table 9.2 Teva: Company Overview

Table 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Table 9.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.5 Novartis: Overview

Table 9.6 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Table 9.7 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.8 Mylan: Company Overview

Table 9.9 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016

Table 9.10 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.11 Pfizer: Company Overview

Table 9.12 Pfizer (Greenstone): Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2016

Table 9.13 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.14 Hospira: Company Overview

Table 9.15 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015

Table 9.16 Abbott: Company Overview

Table 9.17 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016

Table 9.18 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.19 Sun Pharmaceuticals: Company Overview

Table 9.20 Sun Pharma: Historical Generic Drugs Sales ($bn), 2013-2017

Table 9.21 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.22 Aspen: Company Overview

Table 9.23 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2013-2017

Table 9.24 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028

Table 9.25 Fresenius Kabi: Company Overview

Table 9.26 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015

Table 9.27 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028

Table 9.28 Sanofi: Company Overview

Table 9.29 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015

Table 9.30 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028

Table 9.31 Dr. Reddy’s Laboratories Limited: Company Overview

Table 9.32 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017

Table 9.33 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028

Table 9.34 Apotex, Inc.: Company Overview

Table 10.1 SWOT Analysis of the Generic Drugs Market, 2017-2028

Table 11.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2017, 2022 and 2028

Table 11.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2017

Table 11.3 Global Generic Drugs Market Forecast: Revenue ($bn) by Regional Markets, 2017, 2022 and 2028


List of Figures

Figure 1.1 Global Generic Drugs Market Segmentation

Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2017

Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2017

Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2018

Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2017

Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2018

Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2017-2028

Figure 3.6 The Global Generic Drugs Market: Market Share (%) by Region, 2017

Figure 3.7 The Global Generic Drugs Market: Market Share (%) by Region, 2022

Figure 3.8 The Global Generic Drugs Market: Market Share (%) by Region, 2028

Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022

Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2022-2028

Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2028

Figure 3.12 The Global Generic Drugs Market: Market Share (%) by National Markets, 2017

Figure 3.13 The Global Generic Drugs Market: Market Share (%) by National Markets, 2022

Figure 3.14 The Global Generic Drugs Market: Market Share (%) by National Markets, 2028

Figure 3.15 The Global Generic Drugs Market Drivers & Restraints, 2017-2028

Figure 4.1 North America Generic Drugs Market Drivers and Restraints, 2017-2028

Figure 4.2 North America Generic Drugs Market: by Country Value ($bn) and AGR (%) 2017 - 2028

Figure 4.3 U.S. Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 4.4 Canada Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 4.5 North America Generic Drugs Market, % Country Share, 2017

Figure 4.6 North America Generic Drugs Market, % Country Share, 2022

Figure 4.7 North America Generic Drugs Market, % Country Share, 2028

Figure 5.1 Europe Generic Drugs Market: by Country Value ($ bn) and AGR (%) 2017 - 2028

Figure 5.2 Germany Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.3 UK Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.4 France Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.5 Italy Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.6 Spain Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028

Figure 5.7 Europe Generic Drugs Market, % Country Share, 2017

Figure 5.8 Europe Generic Drugs Market, % Country Share, 2022

Figure 5.9 Europe Generic Drugs Market, % Country Share, 2028

Figure 6.1 Asia-Pacific Generic Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 6.2 India Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 6.3 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2017

Figure 6.4 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2022

Figure 6.5 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2028

Figure 6.6 China Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 6.7 Japan Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 6.8 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2017-2028

Figure 6.9 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2017-2028

Figure 6.10 Asia-Pacific Generic Drugs Market, % Country Share, 2017

Figure 6.11 Asia-Pacific Generic Drugs Market, % Country Share, 2022

Figure 6.12 Asia-Pacific Generic Drugs Market, % Country Share, 2028

Figure 7.1 Middle-East & Africa Generic Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 7.2 South Africa Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 7.3 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 7.4 UAE Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 7.5 Middle-East & Africa Generic Drugs Market, % Country Share, 2017

Figure 7.6 Middle-East & Africa Generic Drugs Market, % Country Share, 2022

Figure 7.7 Middle-East & Africa Generic Drugs Market, % Country Share, 2028

Figure 8.1 Latin America Generic Drugs Market Forecast: Revenue ($bn), 2017-2028

Figure 8.2 Brazil Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 8.3 Argentina Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 8.4 Mexico Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 8.5 Latin America Generic Drugs Market, % Country Share, 2017

Figure 8.6 Latin America Generic Drugs Market, % Country Share, 2022

Figure 8.7 Latin America Generic Drugs Market, % Country Share, 2028

Figure 9.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2016

Figure 9.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2017

Figure 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Figure 9.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.5 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Figure 9.6 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.7 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016

Figure 9.8 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.9 Pfizer: Historical ‘Established Products’ Drugs Sales ($bn) and AGR (%), 2014-2016

Figure 9.10 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.11 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015

Figure 9.12 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016

Figure 9.13 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.14 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017

Figure 9.15 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.16 Aspen: Historical Revenue ($bn) and AGR (%), 2013-2017

Figure 9.17 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 9.18 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015

Figure 9.19 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2028

Figure 9.20 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015

Figure 9.21 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2028

Figure 9.22 Dr. Reddy’s: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017

Figure 9.23 Dr. Reddy’s Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028

Figure 10.1 Porter’s Five Force Analysis of the Global Generic Drugs Market, 2017

Figure 11.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2017 2022 and 2028

Abbott

AbbVie

Able Laboratories

Aché

Actavis

Alcon (Novartis)

Allergan (Actavis)

Amgen

Anda Inc

Apotex

APP Pharmaceuticals

Arrow Group (Actavis)

Ascent Pharmahealth (Actavis)

ASKA Pharmaceuticals

Aspen

AstraZeneca

Aurobindo

Auspex Pharmaceuticals

Bedford Laboratories

Bergamo (Amgen)

Biocon

Bioniche Pharma (Mylan)

BMP Sunstone (Sanofi)

Caraco

Celltrion

CFR Pharmaceuticals (Abbott)

Cipla

Claris

Dabur Pharma (Fresenius Kabi)

Daiichi Sankyo

Dalim BioTech

Dr Reddy’s Laboratory

Ebewe Pharma (Novartis)

Eden Biopharm Group

Egis

Elder Pharmaceuticals (Torrent Pharmaceuticals)

Eli Lilly

Elyson Pharmaceuticals

EMS Sigma Pharma

Eon Labs

Eurofarma Laboratories

Farmacias Similares

Fenwal (Fresenius Kabi)

Forest Laboratories (Actavis)

Foshan Chanbende Development

Fougera Pharmaceuticals (Novartis)

Fresenius Kabi

Fresenius SE & Co

Fuji Pharma

Gavis Pharmaceuticals

Gedeon Richter

Genfar S.A (Sanofi)

Genzyme (Sanofi)

Gilead Sciences

GlaxoSmithKline (GSK)

Greenstone (Pfizer)

Grupo Sanborns

Grupo Uriach

Hexal

Hospira (Pfizer)

IDEV Technologies (Abbott)

Ilsung Pharmaceuticals

Imperial Credit Private Limited

InnoPharma Inc

Itero Biopharmaceuticals

Janssen

Javelin Pharmaceuticals (Hospira)

Johnson & Johnson

Kmart

KMS Pharmaceutical

Kowa Pharmaceuticals

Krka

Labesfal Genéricos (Fresenius Kabi)

Laboratorio Sanderson (Fresenius Kabi)

Laboratorios Best

Laboratorios Kendrick (Sanofi)

Lek (Novartis)

Lundbeck

Lupin

Matrix Laboratories

Mayne Pharma (Hospira)

Meda AB

Medley (Sanofi)

Merck KGaA

MN Pharma (Amgen)

Momenta Pharmaceuticals

Mylan

Natco Pharma

Nexus Pharmaceuticals

Nichi-Iko

Nippon Chemiphar

Novartis (Sandoz)

Novo Nordisk

OptiMedica (Abbott)

Orchid Chemicals & Pharmaceuticals

Oriel Therapeutics (Novartis)

Parenteral Drugs India Ltd

Perrigo

Pfizer

Piramal (Abbott Laboratories)

Pliva (Teva)

PT Soho Global Health

Ranbaxy (Sun Pharmaceuticals)

Ratiopharm

Rimsa

Roche

Sabex (Novartis)

Sanofi

Sawai Pharmaceuticals

Schein Pharmaceutical (Actavis)

Servier

Shelys (Aspen)

Sigma Pharmaceuticals (Aspen)

Solvay Pharmaceuticals (Abbott)

Specifar Pharmaceuticals (Actavis)

St. Jude Medical

STADA Arzneimittel

Strides Arcolab

Sun Pharma

Synthon

Taiyo Pharmaceuticals

Takeda

Teuto Brasileiro (Pfizer)

Teva

The Laboratory of Analytical Services International Ltd

Towa

UDL Laboratories

Uteron Pharma (Actavis)

Valeant Pharmaceuticals

Wal-Mart

Warner Chilcott (Actavis)

Watson

Wockhardt

Wyeth (Pfizer)

Zentiva (Sanofi)

Zhejiang Chiral Medicine Chemicals Co. Ltd

Zhejiang Hisun Pharmaceutical

Zydus Cadila


List of Organisations Mentioned in the Report

Assogenerici [Italy]

Blue Cross Blue Shield Association (BCBSA) [US]

British Generic Manufacturers Association (BGMA)

Caisse Nationale de l’Assurance Maladie (CNAM) [France]

Center for Drug Evaluation and Research (CDER) [US]

Centers for Medicare and Medicaid Services [US]

China Food and Drug Administration (CFDA)

COFEPRIS [Mexico]

Competion and Markets Authority (CMA) [UK]

Congressional Budget Office (CBO) [US]

European Commission

European Generics Medicines Association (EGA)

European Medicines Agency (EMA)

European Patent Office (EPO)

Export Council of Australia

Federal Commission for the Protection against Sanitary Risk (COFEPRIS)

Federal Trade Commission (FTC) [US]

Food and Drugs Administration (FDA) [US]

General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]

General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]

Generic Pharmaceutical Association (GPhA)

Gesund­heits­bericht­erstat­tung des Bundes (Federal Health Monitoring System, Germany)

Medical Technology Association of Australia

Medicine and Healthcare products Regulatory Agency (MHRA)

Ministry of Health, Labour and Welfare (MHLW) [Japan]

Ministry of Human Resources and Social Security (MOHRSS)

National Development and Reform Commission (NDRC)

National Health Service (NHS)

National Pharmaceutical Pricing Authority [India]

Pan American Health Organization (PAHO)

Pharmaceutical and Medical Devices Agency (PMDA) [Japan]

Queen Mary University of London

Servicio Sanitario Nazionale (SSN) [Italy]

United Nations’ Department of Economic and Social Affairs

US Generic Pharmaceutical Association (GPhA)

Veropharm (Abbott)

World Health Organization (WHO)

World Trade Organisation (WTO)

Download sample pages

Complete the form below to download your free sample pages for Generic Drugs Market Forecast 2018-2028


Download sample pages

Complete the form below to download your free sample pages for Generic Drugs Market Forecast 2018-2028


Do you have any custom requirements we can help you with?

Any specific country, geo region, market segment or specific company information?

Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

facebookWin a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/

Would you like a free report overview of the report of your choice?

If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

  • Human Microbiome Therapeutics Market 2019-2029
  • Top 20 Urology Companies 2019
  • Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
  • The Top 100 In-Vitro Diagnostics Companies to Watch 2019
  • Global Hypertension Drugs Market 2019-2029
  • The Next Generation Sequencing Market 2019-2029
  • Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
  • Top 25 In Vitro Diagnostics (IVD) Companies 2019
  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
  • Global Biomarkets and Technologies Market 2019-2029
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Latest Pharma news

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

READ

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

READ

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

READ

“Global Oncology Drugs market set to grow to $173bn by 2024” says new Visiongain report

The cancer treating drugs market will continue to grow over the next ten years.

03 May 2019

READ

Categories

Category